JP2022546048A5 - - Google Patents
Info
- Publication number
- JP2022546048A5 JP2022546048A5 JP2022513203A JP2022513203A JP2022546048A5 JP 2022546048 A5 JP2022546048 A5 JP 2022546048A5 JP 2022513203 A JP2022513203 A JP 2022513203A JP 2022513203 A JP2022513203 A JP 2022513203A JP 2022546048 A5 JP2022546048 A5 JP 2022546048A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrimidine
- oxo
- dihydropyrido
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962892799P | 2019-08-28 | 2019-08-28 | |
| US62/892,799 | 2019-08-28 | ||
| PCT/US2020/048070 WO2021041588A1 (en) | 2019-08-28 | 2020-08-27 | Substituted pyridopyrimidinonyl compounds useful as t cell activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546048A JP2022546048A (ja) | 2022-11-02 |
| JP2022546048A5 true JP2022546048A5 (enExample) | 2023-07-20 |
| JP7650864B2 JP7650864B2 (ja) | 2025-03-25 |
Family
ID=72422304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513203A Active JP7650864B2 (ja) | 2019-08-28 | 2020-08-27 | Ｔ細胞アクティベーターとして有用な置換ピリドピリミジノニル化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11584747B2 (enExample) |
| EP (1) | EP4021901B1 (enExample) |
| JP (1) | JP7650864B2 (enExample) |
| KR (1) | KR20220052975A (enExample) |
| CN (1) | CN114302884B (enExample) |
| AR (1) | AR119821A1 (enExample) |
| AU (1) | AU2020336089B2 (enExample) |
| BR (1) | BR112022001862A2 (enExample) |
| CA (1) | CA3149594A1 (enExample) |
| CL (1) | CL2022000485A1 (enExample) |
| CO (1) | CO2022002424A2 (enExample) |
| DK (1) | DK4021901T3 (enExample) |
| ES (1) | ES3057035T3 (enExample) |
| FI (1) | FI4021901T3 (enExample) |
| HR (1) | HRP20251203T1 (enExample) |
| IL (1) | IL290965B1 (enExample) |
| LT (1) | LT4021901T (enExample) |
| MX (1) | MX2022002271A (enExample) |
| PE (1) | PE20220712A1 (enExample) |
| PL (1) | PL4021901T3 (enExample) |
| PT (1) | PT4021901T (enExample) |
| RS (1) | RS67362B1 (enExample) |
| SI (1) | SI4021901T1 (enExample) |
| SM (1) | SMT202500489T1 (enExample) |
| TW (1) | TW202122395A (enExample) |
| WO (1) | WO2021041588A1 (enExample) |
| ZA (1) | ZA202203515B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220236A (es) | 2019-11-28 | 2022-10-03 | Bayer Pharma AG | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune |
| IL294085A (en) * | 2019-12-19 | 2022-08-01 | Bristol Myers Squibb Co | Combinations of dgk inhibitors and checkpoint antagonists |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CA3162979A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
| BR112022012179A2 (pt) | 2019-12-23 | 2022-09-06 | Bristol Myers Squibb Co | Compostos de quinazolina substituída úteis como ativadores de célula t |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| CN115697980B (zh) | 2020-04-24 | 2025-03-21 | 拜耳公司 | 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) * | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| EP4486741A4 (en) | 2022-03-01 | 2026-04-08 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| US20250215014A1 (en) * | 2022-03-31 | 2025-07-03 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| CN117088874A (zh) * | 2022-05-19 | 2023-11-21 | 轩竹生物科技股份有限公司 | 二酰甘油激酶抑制剂及其用途 |
| KR20230164600A (ko) * | 2022-05-25 | 2023-12-04 | 주식회사 엘지화학 | 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도 |
| WO2023229380A1 (ko) * | 2022-05-25 | 2023-11-30 | 주식회사 엘지화학 | 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도 |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| CN117534665A (zh) * | 2022-08-01 | 2024-02-09 | 山东轩竹医药科技有限公司 | 二酰甘油激酶抑制剂 |
| EP4583876A1 (en) * | 2022-09-08 | 2025-07-16 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| BR0312204A (pt) | 2002-06-27 | 2005-04-26 | Schering Ag | Antagonista de receptor ccr5 de quinolina substituìda |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| WO2004087880A2 (en) | 2003-03-26 | 2004-10-14 | Bayer Pharmaceuticals Corporation | Compounds and their use to treat diabetes and related disorders |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| EP1660087A2 (en) | 2003-07-22 | 2006-05-31 | Janssen Pharmaceutica N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| CN1839133A (zh) | 2003-08-22 | 2006-09-27 | 阿文尼尔药品公司 | 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用 |
| US7381401B2 (en) | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| CN103372215B (zh) | 2008-01-03 | 2016-03-09 | 艾克斯-马赛大学 | 抗hiv治疗期间使用的组合物和方法 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010042489A2 (en) | 2008-10-06 | 2010-04-15 | Emory University | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| WO2012142498A2 (en) | 2011-04-13 | 2012-10-18 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR089939A1 (es) | 2012-02-09 | 2014-10-01 | Glenmark Pharmaceuticals Sa | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| PT3889145T (pt) | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| US10946020B2 (en) | 2016-04-06 | 2021-03-16 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US12187687B2 (en) * | 2017-06-26 | 2025-01-07 | University Of Virginia Patent Foundation | Compositions and uses thereof |
| AU2018340475B2 (en) | 2017-09-28 | 2023-01-19 | Transthera Sciences (Nanjing), Inc. | PDE9 inhibitor and use thereof |
| CA3098574A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CN112585139B (zh) | 2018-06-27 | 2023-12-01 | 百时美施贵宝公司 | 用作t细胞激活剂的萘啶酮化合物 |
| KR102767739B1 (ko) | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
-
2020
- 2020-08-25 AR ARP200102382A patent/AR119821A1/es unknown
- 2020-08-26 TW TW109129047A patent/TW202122395A/zh unknown
- 2020-08-27 DK DK20768221.2T patent/DK4021901T3/da active
- 2020-08-27 SM SM20250489T patent/SMT202500489T1/it unknown
- 2020-08-27 AU AU2020336089A patent/AU2020336089B2/en active Active
- 2020-08-27 JP JP2022513203A patent/JP7650864B2/ja active Active
- 2020-08-27 BR BR112022001862A patent/BR112022001862A2/pt unknown
- 2020-08-27 CA CA3149594A patent/CA3149594A1/en active Pending
- 2020-08-27 KR KR1020227009618A patent/KR20220052975A/ko active Pending
- 2020-08-27 EP EP20768221.2A patent/EP4021901B1/en active Active
- 2020-08-27 LT LTEPPCT/US2020/048070T patent/LT4021901T/lt unknown
- 2020-08-27 RS RS20251083A patent/RS67362B1/sr unknown
- 2020-08-27 ES ES20768221T patent/ES3057035T3/es active Active
- 2020-08-27 CN CN202080060991.6A patent/CN114302884B/zh active Active
- 2020-08-27 SI SI202030674T patent/SI4021901T1/sl unknown
- 2020-08-27 PT PT207682212T patent/PT4021901T/pt unknown
- 2020-08-27 HR HRP20251203TT patent/HRP20251203T1/hr unknown
- 2020-08-27 PE PE2022000339A patent/PE20220712A1/es unknown
- 2020-08-27 PL PL20768221.2T patent/PL4021901T3/pl unknown
- 2020-08-27 WO PCT/US2020/048070 patent/WO2021041588A1/en not_active Ceased
- 2020-08-27 US US17/004,058 patent/US11584747B2/en active Active
- 2020-08-27 MX MX2022002271A patent/MX2022002271A/es unknown
- 2020-08-27 FI FIEP20768221.2T patent/FI4021901T3/fi active
-
2022
- 2022-02-27 IL IL290965A patent/IL290965B1/en unknown
- 2022-02-28 CO CONC2022/0002424A patent/CO2022002424A2/es unknown
- 2022-02-28 CL CL2022000485A patent/CL2022000485A1/es unknown
- 2022-03-25 ZA ZA2022/03515A patent/ZA202203515B/en unknown
- 2022-11-08 US US17/983,097 patent/US20230151007A1/en not_active Abandoned
-
2024
- 2024-08-14 US US18/804,699 patent/US20240400563A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546048A5 (enExample) | ||
| HRP20251203T1 (hr) | Supstituirani piridopirimidinonil spojevi korisni kao aktivatori t-stanica | |
| JP5152518B2 (ja) | 置換イソキサゾリン化合物及び有害生物防除剤 | |
| JP2021529191A5 (enExample) | ||
| ES2582575T3 (es) | Procedimiento para la producción de compuesto de amida del ácido benzoico sustituido con isoxazolina | |
| JP5206993B2 (ja) | イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤 | |
| HRP20231253T1 (hr) | Supstituirani spojevi naftiridina korisni kao aktivatori t stanica | |
| JP5316808B2 (ja) | 置換イソキサゾリン又はエノンオキシム化合物および有害生物防除剤 | |
| KR101416521B1 (ko) | 이속사졸린치환 벤즈아미드 화합물 및 유해 생물 방제제 | |
| US8008292B2 (en) | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | |
| KR20070010145A (ko) | 이속사졸린 치환 벤즈아미드 화합물 및 유해생물 방제제 | |
| US8268754B2 (en) | Substituted dihydroazole compound and pest control agent | |
| JP5820056B2 (ja) | Ｃｅｔｐ阻害剤としてのシクロアルケニルアリール誘導体 | |
| JP2017533958A5 (enExample) | ||
| KR20100064382A (ko) | 치환 이속사졸린 화합물 및 유해생물 방제제 | |
| JP2016516737A (ja) | 新規ピリジン誘導体 | |
| KR20090031898A (ko) | 펜타디엔아미드 유도체 | |
| JP2017523223A5 (enExample) | ||
| JP2011037817A (ja) | 殺虫、殺ダニ、殺線虫、殺軟体動物、殺菌又は殺バクテリア剤組成物及び病害虫の防除方法 | |
| WO2017192304A1 (en) | Arylcarboxamides and uses thereof | |
| RU2382784C2 (ru) | Новые пиперидинзамещенные диаминотиазолы | |
| EP2792360A1 (en) | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV | |
| JP2015155401A (ja) | 置換ヘテロ環化合物及び有害生物防除剤 |